The 2020 Focused Updates to the Asthma Management Guidelines: A Report from the
National Asthma Education and Prevention Program Coordinating Committee Expert Panel …

Background Patients' adherence to therapeutic regimes may be influenced by subjective
beliefs about chronic conditions. One of the challenges for health professionals in …

Abstract Background Monoclonal antibodies targeting IgE, interleukin-4 and-13, and
interleukin-5 are effective in treating severe type 2 asthma, but new targets are needed …

Background Tezepelumab is a human monoclonal antibody that blocks thymic stromal
lymphopoietin, an epithelial-cell–derived cytokine implicated in the pathogenesis of asthma …

Background Dupilumab is a fully human anti–interleukin-4 receptor α monoclonal antibody
that blocks both interleukin-4 and interleukin-13 signaling. We assessed its efficacy and …

Background As asthma symptoms worsen, patients typically rely on short-acting β2-agonist
(SABA) rescue therapy, but SABAs do not address worsening inflammation, which leaves …

Background Dupilumab is a fully human anti–interleukin-4 receptor α monoclonal antibody
that blocks both interleukin-4 and interleukin-13 signaling. Its effectiveness in reducing oral …

Background In some patients with moderate-to-severe asthma, particularly those with
noneosinophilic inflammation, the disease remains uncontrolled. This trial evaluated the …

Background Exacerbations of asthma cause a substantial global illness burden. Adults with
uncontrolled persistent asthma despite maintenance treatment require additional therapy …

Importance Although asthma is a chronic disease, the expected rate of spontaneous
remissions of adult asthma and the stability of diagnosis are unknown. Objective To …